Profile: Celgene Corp (CELG.O)
21 Feb 2017
Celgene Corporation (Celgene), incorporated on April 17, 1986, is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). Its clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and a range of international markets. REVLIMID is evaluated in a range of clinical trials around the world either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies. REVLIMID is in several phase III trials across a range of hematological malignancies that include multiple myeloma (MM), lymphomas, chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).
ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy product, which is developed using the Company's nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. ABRAXANE is in various stages of investigation for breast cancer, pancreatic cancer, gastric cancer and non-small cell lung cancer (NSCLC).
POMALYST/IMNOVID is a small molecule, which is administered orally and modulates the immune system and other biologically targets. POMALYST/IMNOVID is also being evaluated in multiple trials in various phases for usage in multiple myeloma.
VIDAZA is a pyrimidine nucleoside analog that has been shown to reverse the effects of deoxyribonucleic acid (DNA) hypermethylation and promote subsequent gene re-expression. VIDAZA is a recommended treatment for patients with intermediate-2 and high-risk MDS. VIDAZA is marketed in the United States and many international markets for the treatment of patients with the various indications, including MDS, All French-American-British (FAB) subtypes and Acute myeloid leukemia (AML).
THALOMID is sold as THALOMID or Thalidomide Celgene outside the United States. THALOMID is administered orally for the treatment of patients with the various indications, including Multiple myeloma and Erythema nodosum leprosum.
OTEZLA is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). OTEZLA is being evaluated in phase III trials for Behcet's disease and expanded indications in psoriatic arthritis and plaque psoriasis.
ISTODAX is administered by intravenous infusion for the treatment of Cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy, and Peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy. It has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, including CTCL and PTCL.
The Company competes with AbbVie, Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Merck, Novartis, Roche/Genentech, Sanofi, Takeda, Biogen, Eli Lilly, Pfizer and UCB S.A.
86 Morris Ave
SUMMIT NJ 07901-3915
Company Web Links
- BRIEF-FDA expands indication for Revlimid in multiple myeloma patients following auto-HSCT
- BRIEF-Celgene reports positive results from Phase III sunbeam trial of oral ozanimod in patients with relapsing multiple sclerosis
- Celgene to pay $198.5 million to settle drug patent licensing case
- BRIEF-Soros Fund Management takes in Facebook, ups in T Mobile and Alphabet
- BRIEF-Neximmune acquired by group of investors led by former Celgene and Medtronic CEOs